Transition from Syringe to Autoinjector Based on Bridging Pharmacokinetics and Pharmacodynamics of the P2Y<sub>12</sub> Receptor Antagonist Selatogrel in Healthy Subjects.

导出原文传递

翻译打印收藏纠错

作者： Isabelle,Zenklusen ^[1] ; Chih-Hsuan,Hsin ^[2] ; Uta,Schilling ^[2] ; Martin,Kankam ^[3] ; Andreas,Krause ^[2] ; Mike,Ufer ^[2] ; Jasper,Dingemanse ^[2]

作者单位： Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123, Allschwil, Switzerland. isabelle.zenklusen@idorsia.com. ^[1] Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123, Allschwil, Switzerland. ^[2] Altasciences Clinical, Inc. 10103 Metcalf Avenue, Overland Park, KS 66212, USA. ^[3]

主题词曲线下面积(Area Under Curve);交叉研究(Cross-Over Studies);人类(Humans);嘧啶类(Pyrimidines);注射器(Syringes);治疗等效(Therapeutic Equivalency)

DOI 10.1007/s40262-021-01097-9

PMID 34961905

发布时间 2022-06-24

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交